Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0598934 (tumor growth)
 58,965 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A long noncoding RNA called LBX2 antisense RNA 1 (LBX2-AS1) has been reported to exert crucial regulatory actions in multiple human cancer types. Nonetheless, the role of LBX2-AS1 in hepatocellular carcinoma (HCC) has not yet been elucidated. Our aim was to determine this role. Reverse-transcription quantitative PCR was conducted to measure LBX2-AS1 expression in HCC. A CCK-8 assay, flow cytometry, Transwell migration and invasion assays, and a xenograft mouse model were employed to determine the impact of LBX2-AS1 on the malignant behavior of HCC cells. Bioinformatics analysis followed by a luciferase reporter assay, RNA immunoprecipitation assay, reverse-transcription quantitative PCR, and western blotting illustrated the mechanisms by which LBX2-AS1 affects the progression of HCC. Herein, expression of LBX2-AS1 was increased in HCC tissues and cell lines. The upregulation of LBX2-AS1 significantly correlated with the tumor node metastasis (TNM) stage and lymph node metastasis in 45 HCC patients. Kaplan-Meier analysis indicated that the upregulation of LBX2-AS1 significantly correlated with shorter overall survival of HCC patients. Functional analyses revealed that knockdown of LBX2-AS1 in HCC cells attenuated their proliferation, migration, and invasion, and induced their apoptosis in vitro and slowed their tumor growth in vivo. Additionally, LBX2-AS1 was found to act as a competing endogenous RNA of microRNA-384 (miR-384), thereby upregulating IRS1. Moreover, miR-384 inhibition weakened the effects of LBX2-AS1 knockdown on HCC cells. The LBX2-AS1-miR-384-IRS1 pathway may be a promising prognostic biomarker and/or a therapeutic target in HCC.
 ...
PMID:Long noncoding RNA LBX2-AS1 drives the progression of hepatocellular carcinoma by sponging microRNA-384 and thereby positively regulating IRS1 expression. 3214 7

As one of the most common cancers in female, ovarian cancer (OC) has become a serious public burden now. Mounting researches have indicated long noncoding RNAs (lncRNAs) can affect many biological processes including cancer development. LncRNA LBX2-AS1 was identified to be an oncogene in some cancers, but the role of LBX2-AS1 in OC remains to be elucidated. Bioinformatics analysis and experiments including ChIP, RT-qPCR, RIP, luciferase reporter, western blot and CCK-8 were performed to explore the role of LBX2-AS1 in OC. LBX2-AS1 expression was markedly increased in OC tissues and cell lines. Functionally, LBX2-AS1 silencing inhibited cell proliferation, migration and stemness but facilitated cell apoptosis in OC. Moreover, depletion of LBX2-AS1 suppressed tumor growth of OC in vivo. Mechanically, LBX2-AS1 was activated by transcriptional factor ELK1. ELK1 enhanced the expression of LBX2-AS1 in OC cells. In addition, miR-4784 was confirmed to be sponged by LBX2-AS1. There was a negative expression correlation between LBX2-AS1 and miR-4784 in OC tissues. Subsequently, KDM5C was identified to be a direct target of miR-4784 in OC cells. KDM5C was negatively regulated by miR-4784 and positively regulated by LBX2-AS1 in terms of expression level. Upregulation of KDM5C reversed the inhibitory effect of LBX2-AS1 depletion on the progression of OC. This study proved that ELK1 activated-LBX2-AS1 aggravated the progression of OC by targeting the miR-4784/KDM5C axis, suggesting that LBX2-AS2 may be a promising diagnostic biomarker of OC.
 ...
PMID:ELK1 activated-long noncoding RNA LBX2-AS1 aggravates the progression of ovarian cancer through targeting miR-4784/KDM5C axis. 3309 20